The Regulator

2.1 billion dollars: that is how much more Medicare will pay the nation’s hospitals next year, in a rule that also forces nearly every one of them into a single national experiment on hip, knee and ankle replacements. The Centers for Medicare and Medicaid Services finalized its fiscal year 2027 Inpatient Prospective Payment System and Long Term Care Hospital rule on July 31, 2026, publishing it in the Federal Register August 4, raising payment rates by a net 2.3 percent for hospitals that report quality data, an increase CMS estimates at $2.1 billion in aggregate plus another $779 million from new medical technology add-on payments. Buried in the same rule is the Comprehensive Care for Joint Replacement Expanded model, or CJR-X, the first time CMS has made an episode-based bundled payment program both mandatory and nationwide, making most acute care hospitals paid under the inpatient system financially responsible for the full cost of hip, knee and ankle replacement care, from surgery through 90 days of recovery, starting January 1, 2028. CMS projects CJR-X will save Medicare $725 million; a hospital must perform at least 31 eligible procedures a year to face full payment reconciliation, though smaller hospitals must still participate and report data. Confidence: High. The Federal Register’s own published rule and CMS’s fact sheet state the dollar figures, dates and model mechanics directly. Sources: Medicare Program; FY 2027 Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System (CMS-1849-F), Federal Register, FY 2027 Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System Final Rule, Centers for Medicare and Medicaid Services.

95 million dollars: that is the wound care Medicare fraud scheme federal prosecutors say a Henderson, Nevada physician ran on elderly beneficiaries, some of them in hospice. A federal grand jury indicted Stephen Dubin, M.D., owner of Dubin Medical Consultants, doing business as Wound MD, the Department of Health and Human Services Office of Inspector General announced August 5, 2026, alleging he billed Medicare more than $95 million for medically unnecessary amniotic wound allografts while collecting illegal kickbacks from two allograft distributors through inflated, sham invoices; Medicare paid out more than $54 million of the scheme before it was stopped. Dubin, 74, faces one count of conspiracy to commit health care fraud and five counts of health care fraud, each carrying up to 10 years in prison, and prosecutors say the proceeds funded a lavish lifestyle including multimillion-dollar yachts. Confidence: Medium. The Department of Justice’s own press release could not be independently retrieved this run, a recurring access problem with justice.gov, but HHS OIG’s enforcement listing confirms the case and dollar figures directly, corroborated by Nevada outlets. Sources: Nevada Doctor Charged with $95M Wound Care Fraud on Medicare, HHS Office of Inspector General, Henderson doctor indicted in $95 million Medicare wound care fraud scheme, Las Vegas Sun.

August 24, 2026: that is the deadline for drugmakers to opt into a rebate system that lets them pay the 340B discount after the sale instead of giving safety net hospitals the price break upfront. The Health Resources and Services Administration issued its Notice Regarding 340B Rebate Model Pilot Program July 31, 2026, published in the Federal Register August 3, its second attempt at a rebate model after a 2025 version was withdrawn following a hospital lawsuit; manufacturers of drugs selected for the Medicare Drug Price Negotiation Program’s 2026 and 2027 initial price applicability years must submit rebate plans to HRSA by August 24, HRSA expects to issue approvals by September 24, and approved plans take effect January 1, 2027. Under the pilot, covered entities such as safety net hospitals and clinics would pay full wholesale acquisition cost upfront and wait for a rebate equal to the 340B discount, a cash flow shift the American Hospital Association is already on record opposing, an objection this newsletter first covered in July over HRSA’s burden estimate for the program. Confidence: High. HRSA’s own notice and the Federal Register filing state the dates and mechanics directly. Sources: Notice Regarding 340B Rebate Model Pilot Program, Federal Register, HRSA Announces Revised 340B Rebate Model Pilot Program to Strengthen Care in Rural and Medically Underserved Communities, Health Resources and Services Administration.

August 7, 2026: that is the deadline for the public to weigh in before Oregon’s attorney general decides whether a financially failing hospital’s takeover can close, after state regulators gave up their own power to review it. Santiam Hospital and Clinics in Stayton and Salem Health Hospitals and Clinics withdrew their pending Health Care Market Oversight review in early July 2026 and asked the Oregon Health Authority for an emergency exemption instead, citing Santiam’s “imminent risk of insolvency.” The state agency granted that exemption July 31, 2026, finding the situation immediately threatens health care services, a designation that strips the Oregon Health Authority of any authority to impose conditions on the deal or conduct follow-up review; the only checkpoint left is the Oregon Department of Justice, which state law requires to approve any hospital affiliation before it closes, and Attorney General Dan Rayfield’s office held a public hearing August 5 with comments so far largely opposed, citing Salem Health’s 2025 decision to drop Regence BlueCross BlueShield from its network. Confidence: High. The Oregon Health Authority’s own case page and the Oregon Department of Justice’s hearing notice state the dates, exemption rationale and comment deadline directly. Sources: Salem Health Hospitals & Clinics, Santiam Hospital & Clinics, Oregon Health Authority, Notice of Public Hearing: Salem Health Affiliation with Santiam Memorial Hospital, Oregon Department of Justice.

90 days: that is how long patients may have to wait for the first drug that treats the full range of narcolepsy type 1 symptoms, because federal drug regulators still have to decide how tightly to control it. The Food and Drug Administration approved Orzeyful, generic name oveporexton, made by the Japanese drugmaker Takeda, on August 5, 2026, the first medicine that treats narcolepsy type 1 by directly targeting its underlying cause, an oral orexin receptor 2 agonist that restores signaling lost when the brain cells that produce orexin die off, rather than treating each symptom, excessive daytime sleepiness, cataplexy and disrupted nighttime sleep, separately. The Drug Enforcement Administration is still reviewing the drug for controlled substance scheduling, a decision FDA and Takeda say is expected within 90 days of approval, and only after that decision will the drug reach patients through a specialty pharmacy. Confidence: High. FDA’s own approval announcement and Takeda’s press release state the mechanism, approval date and pending DEA review directly. Sources: FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms, U.S. Food and Drug Administration, U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1, Takeda.

72 million: that is roughly how many Medicaid and CHIP beneficiaries were the backdrop for dueling Senate testimony this week on whether the program’s spending growth is a policy success or a fraud problem. The Senate Budget Committee held a hearing titled “Medicaid: The Reality” on August 4, 2026, hearing from Brian Blase of the Paragon Health Institute and Jonathan Ingram of the Foundation for Government Accountability, both arguing Medicaid enrollment and spending are unsustainable and prone to fraud, against Andy Schneider of Georgetown University’s Center for Children and Families, who defended home and community based services spending growth as a policy success rather than a fraud story. No bill or markup resulted from the hearing, but it previews the next round of the Medicaid funding fight following 2025’s reconciliation law. Confidence: High on the hearing’s occurrence and witness lineup, stated directly on the committee’s own site; Low on any legislative outcome, since no bill text exists yet. Sources: Medicaid: The Reality, Committee on the Budget, United States Senate.